Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)went up by 3.52% from its latest closing price when compared to the 1-year high value of $7.67 and move down -63.19%, while CPRX stocks collected +0.86% of gains with the last five trading sessions. Press Release reported on 11/12/19 that Catalyst Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Worth an Investment?

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) The 36 Months beta value for CPRX stocks is at 2.41, while of the analysts out of 0 who provided ratings for Catalyst Pharmaceuticals, Inc. stocks as a “buy” while as overweight, rated it as hold and as sell. The average price we get from analysts is $9.00 which is $4.13 above current price. CPRX currently has a short float of 9.08% and public float of 95.72M with average trading volume of 2.38M shares.

CPRX Market Performance

CPRX stocks went up by 0.86% for the week, with the monthly drop of -9.96% and a quarterly performance of -18.40%, while its annual performance rate touched 63.76%. The simple moving average for the period of the last 20 days is -7.87% for CPRX stocks with the simple moving average of 4.04% for the last 200 days.

Analysts’ Opinion on Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Many brokerage firms have already submitted their reports for CPRX stocks, with Cantor Fitzgerald repeating the rating for CPRX shares by setting it to “Overweight”. The predicted price for CPRX socks in the upcoming period according to Cantor Fitzgerald is $0.75 based on the research report published on September 21, 2018.

Piper Jaffray, on the other hand, stated in their research note that they expect to see CPRX stock at the price of $0.75. The rating they have provided for CPRX stocks is “Overweight” according to the report published on September 7, 2018.

CPRX Stocks -13.42% Far from 50 Day Moving Average

After a stumble in the market that brought CPRX to its low price for the period of the last 52 weeks, Catalyst Pharmaceuticals, Inc. was unable to take a rebound, for now settling with -38.72% of loss for the given period.

The stock volatility was left at 6.01%, however, within the period of a single month, the volatility rate increased by 9.20%, while the shares sank at the distance of -11.32% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -24.80% lower at the present time.

In the course of the last 5 trading sessions, CPRX went up by +0.86%, which changed the moving average for the period of 200 days to the total of +86.51% of gains for the stock in comparison to the 20-day moving average settled at $5.07. In addition, Catalyst Pharmaceuticals, Inc. saw 144.79% in overturn over the period of a single year with a tendency to cut further gains.

CPRX Stock Insider Trading

Reports are indicating that there were more than several insider trading activities at Catalyst Pharmaceuticals, Inc. (CPRX), starting from O’Keeffe Charles B, who bought 10,000 shares at the price of $4.70 back on Oct 11. After this action, Rushing now owns 553,376 shares of Catalyst Pharmaceuticals, Inc., valued at $46,950 with the latest closing price.

MCENANY PATRICK J, the President and CEO of Catalyst Pharmaceuticals, Inc., bought 10,000 shares at the value of $4.89 during a trade that took place back on Oct 03, which means that MCENANY PATRICK J is holding 4,772,693 shares at the value of $48,900 based on the most recent closing price.

CPRX Stock Fundamentals

The current profitability levels are settled at -7059.03 for the present operating margin. The net margin for Catalyst Pharmaceuticals, Inc. stands at -6800.70. Total capital return value is set at -53.58, while invested capital returns managed to touch -51.62. Equity return holds the value -21.00%, with -18.00% for asset returns.